128
Participants
Start Date
April 7, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2029
Standard of Care Immune Checkpoint Blockade
Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
LND101
Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
RECRUITING
BCCA - Abbotsford, Abbotsford
RECRUITING
BCCA - Vancouver, Vancouver
RECRUITING
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
RECRUITING
London Health Sciences Centre Research Inc., London
RECRUITING
Ottawa Hospital Research Institute, Ottawa
RECRUITING
Odette Cancer Centre, Toronto
RECRUITING
University Health Network, Toronto
RECRUITING
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
RECRUITING
The Jewish General Hospital, Montreal
RECRUITING
Hotel-Dieu de Quebec, Québec
RECRUITING
Centre hospitalier regional de Trois-Rivieres, Trois-Rivières
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Canadian Cancer Society (CCS)
OTHER
Weston Family Foundation
OTHER
Canadian Cancer Trials Group
NETWORK